Eurofound's EU PolicyWatch collates information on the responses of government and social partners to the COVID-19 crisis, the war in Ukraine, rising inflation, as well as gathering examples of company practices aimed at mitigating the social and economic impacts.
Factsheet for measure FR-2023-42/3405 – Updated – measures in France
| Country | France , applies nationwide |
| Time period | Open ended, started on 17 October 2023 |
| Context | Green Transition |
| Type | Bipartite collective agreements |
| Category |
Reorientation of business activities
– Change of production/Innovation |
| Author | Frédéric Turlan (IRshare), Pascale Turlan (IRshare) and Eurofound |
| Measure added | 12 November 2023 (updated 03 November 2025) |
On 17 October 2023, the employers' organisation LEEM and the CFDT, FO, Unsa and CFTC trade unions signed a collective agreement on the ecological transition and sustainable mobility in the pharmaceutical industry, the first industry-wide agreement on this subject in France. With a view to meet the sector's decarbonisation commitments, companies must carry out a carbon assessment of their activities within 12 months, and then implement an action plan. Companies with more than 300 employees will have to set up an environmental committee responsible for 'studying the environmental impact of the company's strategic decisions or its environmental strategy'.
Having committed to a 50% reduction in direct CO2 emissions and a 25% reduction in indirect emissions, LEEM has proposed a collective agreement on ecological transition and sustainable mobility to the sector's social partners.
Under the terms of this agreement, the sector undertakes, in particular, to set up:
The agreement stipulates that LEEM will provide companies with a number of tools to help them implement ecological transition initiatives. Companies in the sector undertake to implement at least two best practice measures before the end of 2024. These measures may relate to executive remuneration, catering, responsible purchasing or transport, with the introduction of a mobility map if measures are taken on this last point.
The following updates to this measure have been made after it came into effect.
| 24 September 2024 |
The Minister of Labour and Employment extended, by order dated September 24, 2024, and published on Octobre, 8, 2024, the provisions of the agreement of October 17, 2023, on ecological transition and sustainable mobility, concluded under the IDD 176. |
The agreement applies to 93,816 employees on permanent contract and 9,411 employees in short-term contract working the pharmaceutical industry.
| Workers | Businesses | Citizens |
|---|---|---|
|
Employees in standard employment
Workers in non-standard forms of employment |
Sector specific set of companies
|
Does not apply to citizens |
| Actors | Funding |
|---|---|
|
Social partners jointly
|
Companies
Employers organisation |
Social partners' role in designing the measure and form of involvement:
| Trade unions | Employers' organisations | |
|---|---|---|
| Role | Agreed (outcome) incl. social partner initiative | Agreed (outcome) incl. social partner initiative |
| Form | Not applicable | Not applicable |
Social partners' role in the implementation, monitoring and assessment phase:
The employers' organisation LEEM has signed the agreement with four trade unions (CFDT, Force Ouvrière, UNSA and CFTC) which represented 62.94% of the votes in the last professional elections, enabling the agreement to be validated.
No information.
This case is sector-specific (only private sector)
| Economic area | Sector (NACE level 2) |
|---|---|
| C - Manufacturing | C20 Manufacture of chemicals and chemical products |
This case is not occupation-specific.
Citation
Eurofound (2023), Collective agreement on ecological transition and sustainable mobility in the pharmaceutical industry, measure FR-2023-42/3405 (measures in France), EU PolicyWatch, Dublin, https://static.eurofound.europa.eu/covid19db/cases/FR-2023-42_3405.html
Share
All publications are available on the EU PolicyWatch landing page .
Disclaimer: This information has not been subject to the full Eurofound evaluation, editorial and publication process.